Gary Sender
Directeur/Membre du Conseil chez SCHRÖDINGER, INC.
Fortune : 218 457 $ au 30/06/2024
Profil
Gary L.
Sender is currently an Independent Director at Schrödinger, Inc., iBio, Inc., Elucida Oncology, Inc., Harmony Biosciences Holdings, Inc., and Gennao Bio, Inc. He is also a Director at Harmony Biosciences LLC.
In the past, he worked as Senior Vice President-Finance at Shire Plc, CFO and Vice President-Finance & Administration at Tengion, Inc., Chief Financial Officer at Nabriva Therapeutics GmbH and Synergy Pharmaceuticals LLC, and Chief Financial Officer at Nabriva Therapeutics Plc.
He also held a position as Head-Investor Relations & Treasury at Merck & Co. Mr. Sender holds an MBA from Carnegie Mellon University and an undergraduate degree from Boston University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SCHRODINGER, INC.
0,02% | 18/06/2024 | 11 250 ( 0,02% ) | 217 575 $ | 30/06/2024 |
IBIO, INC.
0,00% | 25/10/2023 | 418 ( 0,00% ) | 882 $ | 30/06/2024 |
| 29/05/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Gary Sender
| Sociétés | Poste | Début |
|---|---|---|
| SCHRÖDINGER, INC. | Directeur/Membre du Conseil | 01/07/2019 |
| IBIO, INC. | Directeur/Membre du Conseil | 14/10/2020 |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Directeur/Membre du Conseil | 01/08/2020 |
Elucida Oncology, Inc.
 Elucida Oncology, Inc. BiotechnologyHealth Technology Elucida Oncology, Inc. operates as a biotechnology company which focuses on clinical research and development. The company was founded by Isaac Blech, Michelle Bradbury, Ulrich Weisner, and Steven Larson in 2014 and is headquartered in Monmouth Junction, NJ. | Directeur/Membre du Conseil | 29/04/2021 |
Harmony Biosciences LLC
 Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | Directeur/Membre du Conseil | - |
Gennao Bio, Inc.
 Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Directeur/Membre du Conseil | 08/09/2021 |
Anciens postes connus de Gary Sender
| Sociétés | Poste | Fin |
|---|---|---|
| NABRIVA THERAPEUTICS PLC | Directeur Financier/CFO | 12/03/2021 |
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Directeur Financier/CFO | 23/06/2017 |
| SYNERGY PHARMACEUTICALS INC | Directeur Financier/CFO | 30/04/2016 |
| ░░░░░ ░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Gary Sender
| Boston University | Undergraduate Degree |
| Carnegie Mellon University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| TENGION, INC. | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| SCHRÖDINGER, INC. | Technology Services |
| IBIO, INC. | Health Technology |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Synergy Pharmaceuticals LLC
 Synergy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Synergy Pharmaceuticals LLC engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai and is headquartered in New York, NY. | Health Technology |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
| Merck & Co. | Finance |
Elucida Oncology, Inc.
Elucida Oncology, Inc. BiotechnologyHealth Technology Elucida Oncology, Inc. operates as a biotechnology company which focuses on clinical research and development. The company was founded by Isaac Blech, Michelle Bradbury, Ulrich Weisner, and Steven Larson in 2014 and is headquartered in Monmouth Junction, NJ. | Health Technology |
Harmony Biosciences LLC
Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | Health Technology |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Health Technology |
